Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 13/20 | 0.41 |
| ▸ | F11 | P03951 | 5/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.41 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14692557 | 0.87 | EGLN1 (0.53) | NOTUMKLKB1F11EGLN1ALKBH1 | |
| SCHEMBL15933313 | 0.86 | NOTUM (0.43) | NOTUMF11EGLN1ALKBH1 | |
| SCHEMBL17324825 | 0.85 | EGLN1 (0.46) | NOTUMEGLN1ALKBH1 | |
| SCHEMBL15930130 | 0.85 | NOTUM (0.40) | NOTUMKLKB1F11EGLN1ALKBH1 | |
| SCHEMBL20647112 | 0.85 | RXRA (0.43) | NOTUMKLKB1F11EGLN1ALKBH1 | |
| SCHEMBL17365301 | 0.84 | RXRA (0.40) | NOTUMEGLN1ALKBH1RXRAGRIN1 | |
| SCHEMBL14947694 | 0.80 | ALKBH2 (0.45) | NOTUMEGLN1ALKBH1MAPK8 | |
| SCHEMBL10265054 | 0.78 | RXRA (0.50) | NOTUMKLKB1RXRAGRIN1GRIN2B | |
| SCHEMBL17570893 | 0.78 | EGLN1 (0.38) | KLKB1EGLN1ALKBH1 | |
| SCHEMBL17365308 | 0.75 | ALDH1A1 (0.43) | NOTUMEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954681-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3402790-B1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-10-06 | — | — | EP | disclosed |
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-31 | — | — | US | disclosed |
| US-9902742-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170158712-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2739628-B1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9611274-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160068544-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-9221818-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140221338-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | NOTUM 2506/4885KLKB1 12/4885F11 4/4885 |
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | TFPI, TFPI2, F12 | NOTUM 2611/4885KLKB1 14/4885F11 4/4885 |
| US-20160068544-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | NOTUM 2506/4885KLKB1 12/4885F11 4/4885 |
| US-20140221338-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | NOTUM 2506/4885KLKB1 12/4885F11 4/4885 |
| US-20170158712-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | NOTUM 2506/4885KLKB1 12/4885F11 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.